CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 122 filers reported holding CRINETICS PHARMACEUTICALS IN in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $512,430 | +52.7% | 18,600 | 0.0% | 0.10% | +41.9% |
| Q2 2023 | $335,544 | -1.4% | 18,600 | 0.0% | 0.07% | -42.6% |
| Q4 2022 | $340,380 | -3.6% | 18,600 | 0.0% | 0.13% | +50.0% |
| Q3 2022 | $353,000 | +0.6% | 18,600 | 0.0% | 0.09% | +11.7% |
| Q2 2022 | $351,000 | -14.0% | 18,600 | 0.0% | 0.08% | -2.5% |
| Q1 2022 | $408,000 | -22.0% | 18,600 | 0.0% | 0.08% | -12.2% |
| Q4 2021 | $523,000 | +42.1% | 18,600 | 0.0% | 0.09% | +34.3% |
| Q3 2021 | $368,000 | -5.2% | 18,600 | 0.0% | 0.07% | -10.7% |
| Q2 2021 | $388,000 | +26.8% | 18,600 | 0.0% | 0.08% | +15.4% |
| Q1 2021 | $306,000 | +16.3% | 18,600 | 0.0% | 0.06% | +8.3% |
| Q4 2020 | $263,000 | -15.4% | 18,600 | 0.0% | 0.06% | -29.4% |
| Q3 2020 | $311,000 | – | 18,600 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 410,360 | $11,658,000 | 6.24% |
| 5AM Venture Management, LLC | 862,286 | $24,498,000 | 4.60% |
| Bain Capital Life Sciences Investors, LLC | 2,029,701 | $57,664,000 | 4.57% |
| Opaleye Management Inc. | 724,400 | $20,580,000 | 4.36% |
| Deep Track Capital, LP | 1,900,000 | $53,979,000 | 3.81% |
| BVF INC/IL | 3,003,879 | $85,340,000 | 3.10% |
| FRAZIER MANAGEMENT LLC | 1,384,293 | $39,328,000 | 3.03% |
| Altium Capital Management LP | 331,000 | $9,404,000 | 2.59% |
| Perceptive Advisors | 10,327,034 | $293,392,000 | 2.26% |
| MPM BioImpact LLC | 379,792 | $10,790,000 | 1.97% |